Review of Myopia Management

1 week ago | reviewofmm.com | Kristen Dalli

June 18, 2025FRANCE — HOYA Vision Care announced that France has become the first country in the European Union (EU) to offer reimbursement for MiYOSMART* lenses for myopia management. Following an in-depth review by the French Health Authority (HAS), this decision will significantly expand access for children affected by severe and progressive myopia.

1 week ago | reviewofmm.com | Kristen Dalli

A new study conducted by researchers from the University of Houston explored how multifocal contact lenses help fight myopia. David Berntsen, Golden-Golden Professor of Optometry and chair of Clinical Sciences at the University of Houston College of Optometry, and the BLINK (Bifocal Lenses In Nearsighted Kids) Study team conducted the trial. The biggest finding: having myopic children wear high-add power multifocal contact lenses slows myopia progression.

2 weeks ago | reviewofmm.com | Kristen Dalli

sponsored contentJune 16, 2025It’s never too early for practices to lay the groundwork for the busy back-to-school season. If you’re looking for ways to motivate parents to include a comprehensive eye exam on their child’s back-to-school checklist, CooperVision and The Myopia Collective offer a wealth of resources to help. Practice ResourcesHere are eight ready-made resources courtesy of CooperVision and The Myopia Collective to bolster your practice’s back-to-school action plan.

2 weeks ago | reviewofmm.com | Kristen Dalli

June 11, 2025ROCHESTER, N.Y. — CooperVision recently hosted its 2025 New Graduate Summit on both the East and West Coast. The company welcomed over 100 new Doctors of Optometry for two multi-day educational events. The goal of the Summit was to support the transition from optometry school to practice. The Summits provided practical guidance on topics including employment contracts, financial planning and building confidence in patient care, among others.

3 weeks ago | reviewofmm.com | Kristen Dalli

June 6, 2025DEL MAR, Calif. — Sydnexis‘ proprietary low-dose atropine formulation, SYD-101, has received marketing authorization from the European Commission (EC). SYD-101 is the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries. This approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis’ pivotal Phase 3 clinical trial.